Voyager Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

VYGR$1.83-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(amounts in thousands, except share data)


· · · · · · · · · · Accumulated · · · · · ·
· · · · · · · Additional · · Other · · · · ·
· · Common Stock · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’
	Shares		Amount		Capital		(Loss) Income		Deficit		Equity

Balance at December 31, 2022		38,613,891		$38		$452,713		$(219)		$(393,512)		59,020
Exercises of vested stock options		51,993		—		185		—		—		185
Vesting of restricted stock units		374,417		—		—		—		—		—
Issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement		4,395,588		5		31,116		—		—		31,121
Stock-based compensation expense		—		—		2,504		—		—		2,504
Unrealized gain on available-for-sale securities, net of tax		—		—		—		87		—		87
Net income		—		—		—		—		124,044		124,044
Balance at March 31, 2023		43,435,889		$43		$486,518		$(132)		$(269,468)		$216,961
Exercises of vested stock options		198,348		1		1,228		—		—		1,229
Vesting of restricted stock units		62,828		—		—		—		—		—
Issuance of common stock under ESPP		62,344		—		418		—		—		418
Stock-based compensation expense		—		—		2,627		—		—		2,627
Unrealized loss on available-for-sale securities, net of tax		—		—		—		(1)		—		(1)
Net loss		—		—		—		—		(22,208)		(22,208)
Balance at June 30, 2023		43,759,409		$44		$490,791		$(133)		$(291,676)		$199,026
Exercises of vested stock options		127,252		—		415		—		—		415
Vesting of restricted stock units		22,500		—		—		—		—		—
Stock-based compensation expense		—		—		2,795		—		—		2,795
Unrealized loss on available-for-sale securities, net of tax		—		—		—		(115)		—		(115)
Net loss		—		—		—		—		(25,901)		(25,901)
Balance at September 30, 2023		43,909,161		$44		$494,001		$(248)		$(317,577)		$176,220

Balance at December 31, 2023		44,038,333		$44		$497,506		$(48)		$(261,182)		$236,320
Exercises of vested stock options		32,500		—		78		—		—		78
Vesting of restricted stock units		324,520		—		—		—		—		—
Issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement		2,145,002		2		19,303		—		—		19,305
Issuance of common stock and pre-funded warrants in connection with underwritten public offering		7,777,778		8		93,465		—		—		93,473
Stock-based compensation expense		—		—		3,498		—		—		3,498
Unrealized loss on available-for-sale securities, net of tax		—		—		—		(458)		—		(458)
Net loss		—		—		—		—		(11,330)		(11,330)
Balance at March 31, 2024		54,318,133		$54		$613,850		$(506)		$(272,512)		$340,886
Exercises of vested stock options		25,958		—		90		—		—		90
Vesting of restricted stock units		56,549		—		—		—		—		—
Issuance of common stock under ESPP		71,473		—		639		—		—		639
Stock-based compensation expense		—		—		3,959		—		—		3,959
Unrealized loss on available-for-sale securities, net of tax		—		—		—		(16)		—		(16)
Net loss		—		—		—		—		(10,141)		(10,141)
Balance at June 30, 2024		54,472,113		$54		$618,538		$(522)		$(282,653)		$335,417
Exercises of vested stock options		27,642		—		92		—		—		92
Vesting of restricted stock units		42,293		1		—		—		—		1
Stock-based compensation expense		—		—		3,355		—		—		3,355
Unrealized gain on available-for-sale securities, net of tax		—		—		—		489		—		489
Net loss		—		—		—		—		(9,044)		(9,044)
Balance at September 30, 2024		54,542,048		$55		$621,985		$(33)		$(291,697)		$330,310

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.